Results 21 to 30 of about 1,006,148 (403)

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]

open access: yes, 2016
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves   +37 more
core   +1 more source

YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner.

open access: yesBlood, 2021
RNA-binding proteins (RBPs) are critical regulators of transcription and translation that are often dysregulated in cancer. Although RBPs are increasingly appreciated as being important for normal hematopoiesis and for hematological malignancies as ...
Mengdie Feng   +24 more
semanticscholar   +1 more source

Priapism as the first symptom of chronic myeloid leukemia: literature review and own clinical case report

open access: yesОнкогематология, 2022
Chronic myeloid leukemia is a ph-positive myeloproliferative disease, which is usually manifested by hyperleukocytosis and massive splenomegaly. Chronic myeloid leukemia is rare in childhood and adolescence, it accounts for 2 to 3 % of all leukemias ...
T. Yu. Pavlova, T. T. Valiev
doaj   +1 more source

Somatic mutations precede acute myeloid leukemia years before diagnosis

open access: yesNature Medicine, 2018
Pinkal Desai   +2 more
exaly   +2 more sources

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

open access: yesNew England Journal of Medicine, 2013
BACKGROUND Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not yet clear.
T. Ley   +99 more
semanticscholar   +1 more source

De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

open access: yesCancer, 2021
Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of acute myeloid leukemia (AML).
K. Sasaki   +7 more
semanticscholar   +1 more source

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

open access: yesHaematologica, 2019
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid ...
Jianbiao Zhou   +13 more
doaj   +1 more source

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report [PDF]

open access: yes, 2014
Case presentation. We report the case of a 64-year-old Caucasian man diagnosed with chronic-phase chronic myeloid leukemia in April 2005. After 4 years of treatment with imatinib, he became intolerant to the drug and was switched to nilotinib.
CAOCCI, GIOVANNI   +2 more
core   +2 more sources

Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future

open access: yesCells, 2021
Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after ...
Valentina R Minciacchi   +2 more
semanticscholar   +1 more source

Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice

open access: yesHaematologica, 2008
We investigated the NPM1 mutation status or subcellular expression of NPM protein (nuclear vs. aberrant cytoplasmic) at diagnosis and relapse in 125 patients with acute myeloid leukemia from Italy and Germany.
Brunangelo Falini   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy